HRP20221414T1 - Antifungalni agensi sa pojačanom aktivnošću kod kiselog ph - Google Patents

Antifungalni agensi sa pojačanom aktivnošću kod kiselog ph Download PDF

Info

Publication number
HRP20221414T1
HRP20221414T1 HRP20221414TT HRP20221414T HRP20221414T1 HR P20221414 T1 HRP20221414 T1 HR P20221414T1 HR P20221414T T HRP20221414T T HR P20221414TT HR P20221414 T HRP20221414 T HR P20221414T HR P20221414 T1 HRP20221414 T1 HR P20221414T1
Authority
HR
Croatia
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
iia
formula
Prior art date
Application number
HRP20221414TT
Other languages
English (en)
Croatian (hr)
Inventor
David A. ANGULO GONZALEZ
Original Assignee
Scynexis, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63209698&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20221414(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Scynexis, Inc. filed Critical Scynexis, Inc.
Publication of HRP20221414T1 publication Critical patent/HRP20221414T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HRP20221414TT 2017-08-04 2018-07-31 Antifungalni agensi sa pojačanom aktivnošću kod kiselog ph HRP20221414T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762541370P 2017-08-04 2017-08-04
EP18755632.9A EP3661503B1 (en) 2017-08-04 2018-07-31 Antifungal agents with enhanced activity in acidic ph
PCT/US2018/044619 WO2019028034A1 (en) 2017-08-04 2018-07-31 Antifungal agents with enhanced activity in acidic ph

Publications (1)

Publication Number Publication Date
HRP20221414T1 true HRP20221414T1 (hr) 2023-01-20

Family

ID=63209698

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20221414TT HRP20221414T1 (hr) 2017-08-04 2018-07-31 Antifungalni agensi sa pojačanom aktivnošću kod kiselog ph

Country Status (26)

Country Link
US (3) US11534433B2 (cg-RX-API-DMAC7.html)
EP (3) EP4169514B1 (cg-RX-API-DMAC7.html)
JP (1) JP7214714B2 (cg-RX-API-DMAC7.html)
KR (1) KR102807716B1 (cg-RX-API-DMAC7.html)
CN (2) CN118542868A (cg-RX-API-DMAC7.html)
AU (2) AU2018309718B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020002290A2 (cg-RX-API-DMAC7.html)
CA (1) CA3071940A1 (cg-RX-API-DMAC7.html)
CY (1) CY1125690T1 (cg-RX-API-DMAC7.html)
DK (1) DK3661503T3 (cg-RX-API-DMAC7.html)
EA (1) EA202090445A1 (cg-RX-API-DMAC7.html)
ES (2) ES2932658T3 (cg-RX-API-DMAC7.html)
FI (1) FI3661503T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20221414T1 (cg-RX-API-DMAC7.html)
HU (1) HUE060508T2 (cg-RX-API-DMAC7.html)
LT (1) LT3661503T (cg-RX-API-DMAC7.html)
MA (1) MA49751B1 (cg-RX-API-DMAC7.html)
MD (1) MD3661503T2 (cg-RX-API-DMAC7.html)
MX (1) MX2020001399A (cg-RX-API-DMAC7.html)
PL (1) PL3661503T3 (cg-RX-API-DMAC7.html)
PT (1) PT3661503T (cg-RX-API-DMAC7.html)
RS (1) RS63746B1 (cg-RX-API-DMAC7.html)
SI (1) SI3661503T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202200461T1 (cg-RX-API-DMAC7.html)
TW (1) TWI805600B (cg-RX-API-DMAC7.html)
WO (1) WO2019028034A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020228036B2 (en) * 2019-02-27 2025-08-07 Scynexis, Inc. Triterpenoid antifungals for the treatment or prevention of Pneumocystis spp. pneumonia
AU2020276595B2 (en) * 2019-05-16 2025-12-04 Scynexis, Inc. Antifungal Agents for Candida Auris Decolonization
WO2022140646A1 (en) * 2020-12-26 2022-06-30 Mycovia Pharmaceuticals, Inc Dosing regimen for oteseconazole

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756472A (en) 1996-01-31 1998-05-26 Merck & Co., Inc. Antifungal agent obtained from hormonema
ES2402659T3 (es) 2006-04-03 2013-05-07 Merck Sharp & Dohme Corp. Derivados de enfumafungina como agentes antifúngicos
WO2010019204A1 (en) 2008-08-12 2010-02-18 Merck Sharp & Dohme Corp. Antifungal agents
BRPI0912074B1 (pt) * 2008-08-12 2021-08-03 Merck Sharp & Dohme Corp Composto e composição farmacêutica
PT3247711T (pt) 2015-01-19 2022-05-16 Scynexis Inc Novos sais e polimorfos de scy-078
JP7263313B2 (ja) * 2017-04-10 2023-04-24 サイネクシス,インコーポレーテッド 併用される抗真菌剤

Also Published As

Publication number Publication date
US20200390751A1 (en) 2020-12-17
CN118542868A (zh) 2024-08-27
EP4169514B1 (en) 2026-01-28
SMT202200461T1 (it) 2023-01-13
MD3661503T2 (ro) 2023-01-31
KR20200044823A (ko) 2020-04-29
CA3071940A1 (en) 2019-02-07
AU2024227501A1 (en) 2024-11-07
TWI805600B (zh) 2023-06-21
BR112020002290A2 (pt) 2020-09-08
US20260000656A1 (en) 2026-01-01
HUE060508T2 (hu) 2023-03-28
JP7214714B2 (ja) 2023-01-30
PL3661503T3 (pl) 2023-01-09
CN111093655A (zh) 2020-05-01
AU2018309718A1 (en) 2020-02-27
SI3661503T1 (sl) 2023-01-31
MX2020001399A (es) 2020-08-06
MA49751B1 (fr) 2022-12-30
TW201919476A (zh) 2019-06-01
LT3661503T (lt) 2022-12-12
WO2019028034A1 (en) 2019-02-07
PT3661503T (pt) 2022-12-13
RS63746B1 (sr) 2022-12-30
EP4169514A1 (en) 2023-04-26
EP3661503A1 (en) 2020-06-10
JP2020529999A (ja) 2020-10-15
DK3661503T3 (da) 2022-12-12
FI3661503T3 (fi) 2022-12-15
MA49751A (fr) 2020-06-10
US20230364067A1 (en) 2023-11-16
KR102807716B1 (ko) 2025-05-13
CY1125690T1 (el) 2026-02-25
EP3661503B1 (en) 2022-09-07
EP4732902A3 (en) 2026-07-22
US11534433B2 (en) 2022-12-27
ES2932658T3 (es) 2023-01-23
EA202090445A1 (ru) 2020-06-23
EP4732902A2 (en) 2026-04-29
AU2018309718B2 (en) 2024-07-25
EP4169514C0 (en) 2026-01-28
ES3068719T3 (en) 2026-06-02

Similar Documents

Publication Publication Date Title
HRP20231276T1 (hr) Inhibitor egfr-a za liječenje raka
PY2086023A (es) Derivados de pirazolilo útiles como agentes anticancerígenos
HRP20221086T1 (hr) Spojevi za liječenje karcinoma
IL305910B1 (en) Oral dosage formulation of {[ 5-(3- (chlorophenyl)- 3-hydroxypyridine-2- carbonyl] amino} acetic acid
FI3593817T3 (fi) Koostumus käytettäväksi likinäköisyyden ehkäisyssä tai vähentämisessä
MA54411B1 (fr) Compositions contenant de l'ibrutinib
JP2015078230A5 (cg-RX-API-DMAC7.html)
JP2014516942A5 (cg-RX-API-DMAC7.html)
HRP20161674T1 (hr) 4-(8-METOKSI-1-((1-METOKSIPROPAN-2-IL)-2-(TETRAHIDRO-2H-PIRAN-4-IL)-1H-IMIDAZO[4,5-c]KINOLIN-7-IL)-3,5-DIMETILIZOKSAZOL I NJEGOVA UPOTREBA KAO INHIBITORA BROMODOMENE
AR075179A1 (es) Formulaciones galenicas de compuestos organicos que comprenden alisquireno
US20110028510A1 (en) Compositions, Methods, and Kits for Treating Influenza Viral Infections
JP2014511393A5 (cg-RX-API-DMAC7.html)
FI3661503T3 (fi) PARANTUNEEN AKTIIVISUUDEN HAPPAMASSA pH:SSA OMAAVIA SIENILÄÄKKEITÄ
HRP20251001T1 (hr) Inhibitor brutonove tirozin kinaze za upotrebu u liječenju kronične spontane urtikarije
MA53927B1 (fr) Composition pharmaceutique pour une administration par voie orale comprenant un dérivé d'aminopyrimidine ou son sel
FI3897646T3 (fi) Masitentaani keuhkovaltimoverenpainetaudin hoitoon
JP2020100627A (ja) 15−hepeを含む組成物及びそれを使用する方法
MX388825B (es) Uso y dosificacion de agentes terapeuticos para endometriosis.
IL270394B (en) Dementia therapeutic agent combining pyrazoloquinoline derivative and memantine
JP2020529999A5 (cg-RX-API-DMAC7.html)
CN105879031A (zh) 协同治疗肿瘤的非抗癌药组合物
CA2660939A1 (en) Pharmaceutical compositions for the treatment of fungal infections
HRP20231448T1 (hr) Primjena delgocitiniba za liječenje kroničnog ekcema ruku
MY195054A (en) Pharmaceutical Composition Comprising Mineralocorticoid Receptor Antagonist and use Thereof
PH12022550917A1 (en) Use of phenylquinolinones and flavonoid derivatives for treating neuropathic pain